In 3032 patients with diabetes undergoing PCI, the Abluminus DES+ sirolimus-eluting stent failed non-inferiority versus the XIENCE everolimus-eluting stent at 12 months: target-lesion revascularisation 4.8% vs 2.1% and target-lesion failure 9.7% vs 6.2%.
RCTn = 3,032
Abizaid et al. Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial